Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus

NCT06153095 is registered in ClinicalTrials.gov with Lyell Immunopharma, Inc. as lead sponsor.

NCT NCT06153095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06153095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of IMPT-514 in Participants With Active, Refractory Lupus Nephritis and Systemic Lupus Erythematosus
Lead sponsor
Lyell Immunopharma, Inc.
Phase
Phase 1/2
Overall status
Withdrawn
Start date
February 15, 2024
Completion date
January 9, 2025
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

lupus nephritis, systemic lupus erythematosus